Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Hyrulean King who wrote (1961)	6/27/1998 8:37:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 5402

this older study notes that 20-30 ml/kg appear to be safe..in humans Prog Clin Biol Res 1983;122:343-351 Effect of Fluosol-DA on the blood coagulation/fibrinolytic system and the renin-angiotensin system in man. Yoshimura N, Gushiken T, Horinokuchi N, Kawasaki K, Maruyama I Either F-DA, Ringer's lactate or HES was given to three groups of six patients each who were undergoing elective gynecologic surgery, and their effects on the blood coagulation/fibrinolytic systems, and the renin-angiotensin systems were evaluated. Platelet counts were found to increase markedly using the Coulter Counter method, but no change was observed when the Rees-Ecker method was used. Platelet aggregation was inhibited and AT-III concentrations were decreased by administration of F-DA. There were no significant changes in PT or a-PTT as a result of F-DA administration. Similarly, there were no significant changes in the concentrations of fbg, FDP, a2-PI, P-FN and renin, angiotensin I, II and angiotensin converting enzyme following F-DA administration. Based upon these findings, it is suggested that a clinical dosage of 20 to 30 ml/kg of F-DA can be safely administered to patients with normal platelet and RES function.